Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Acetyl-L-Carnitine in the Treatment of Septic Shock (ALC)

This study has been completed.
Information provided by (Responsible Party):
Todd Rice, Vanderbilt University Identifier:
First received: January 2, 2008
Last updated: January 16, 2014
Last verified: January 2014
This placebo-controlled study investigates acetyl-L-carnitine in the treatment of septic shock requiring vasopressors.

Condition Intervention Phase
Septic Shock
Drug: Acetyl-L-Carnitine
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Prospective, Randomized, Placebo-controlled, Double-Blinded, Phase II Pilot Study of Acetyl-L-carnitine in the Treatment of Patients With Septic Shock

Resource links provided by NLM:

Further study details as provided by Vanderbilt University:

Primary Outcome Measures:
  • Mean Arterial Blood Pressure [ Time Frame: 18 hours ]
    Mean Arterial blood pressure measured non-invasively at 18 hours

  • Vasopressor Dose [ Time Frame: 6-24 hours ]

Secondary Outcome Measures:
  • Serum Lactate [ Time Frame: 12-36 hours ]

Enrollment: 13
Study Start Date: August 2006
Study Completion Date: September 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo for first 6 hours then Acetyl-L-Carnitine (ALC) for 12 hours
Drug: Acetyl-L-Carnitine
Acetyl-L-Carnitine - 4 g IV over 30 minutes, then 8 g iv over the next 12 hours
Other Name: ALC
Acetyl-L-Carnitine (ALC) for first 12 hours then placebo for next 6 hours
Drug: Acetyl-L-Carnitine
Acetyl-L-Carnitine - 4 g IV over 30 minutes, then 8 g iv over the next 12 hours
Other Name: ALC

Detailed Description:
This is a cross-over study which infuses ALC for 12 out of 18 hours (and placebo the other 6). Patients must have vasopressor-dependent septic shock and be free from renal failure, hepatic failure, and seizures to be eligible.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • documented or presumed infection
  • shock requiring vasopressors

Exclusion Criteria:

  • dialysis
  • hepatic failure
  • seizures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00592488

United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University
Principal Investigator: Todd W. Rice, MD, MSc Vanderbilt University
  More Information

Responsible Party: Todd Rice, Assistant Professor, Vanderbilt University Identifier: NCT00592488     History of Changes
Other Study ID Numbers: 050730
Study First Received: January 2, 2008
Results First Received: March 17, 2011
Last Updated: January 16, 2014

Keywords provided by Vanderbilt University:
Septic shock

Additional relevant MeSH terms:
Shock, Septic
Pathologic Processes
Systemic Inflammatory Response Syndrome
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs
Nootropic Agents processed this record on May 23, 2017